BioCatalystWatch
ENGNWorkspace / ENGN / OverviewCompany library
enGene Therapeutics Inc. logo

enGene Therapeutics Inc.

enGene Therapeutics Inc. (ENGN)

Website

Price
Market cap
Next catalyst4Q 2026Detalimogene voraplasmid (EG-70) — LEGEND · Regulatory meetingSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Detalimogene voraplasmidDetalimogene voraplasmid (EG-70) — LEGEND

RIG-I

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Detalimogene voraplasmidDetalimogene voraplasmid (EG-70) — LEGEND

RIG-I

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ENGN PR & News

PR & News

ENGN SEC archive